Antibodies for determining coagulation factor viii activity and assays
By using anti-ELNN antibodies and colorimetric assays, the challenge of measuring the activity of chimeric protein FVIII in patients with von Willebrand disease has been solved, providing accurate monitoring of FVIII activity, reducing the risk of joint bleeding, and improving the accuracy of treatment management.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- AMUNIX PHARMACEUTICALS INC
- Filing Date
- 2024-12-18
- Publication Date
- 2026-07-17
AI Technical Summary
Existing technologies make it difficult to accurately measure the activity level of coagulation factor VIII in patients with von Willebrand disease who have been given chimeric proteins such as enothrombin α. In particular, the level of FVIII is significantly reduced in patients with type 2N and type 3 VWD, leading to complications such as joint bleeding.
Chimeric proteins were isolated from patient samples using anti-ELNN antibodies or their antigen-binding fragments, and FVIII activity was measured using a colorimetric assay. The measured values were corrected as necessary to provide accurate FVIII activity levels.
This technology enables accurate measurement of the activity of chimeric protein FVIII in patients with von Willebrand disease, helping to monitor and manage treatment outcomes and reduce the risk of joint bleeding.
Smart Images
Figure CN122422346A_ABST